Edition:
United States

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

7.32USD
16 Jul 2018
Change (% chg)

$0.05 (+0.69%)
Prev Close
$7.27
Open
$7.30
Day's High
$7.36
Day's Low
$7.13
Volume
111,909
Avg. Vol
282,570
52-wk High
$7.55
52-wk Low
$2.10

Select another date:

Tue, May 8 2018

BRIEF-Cerus Corp Reports Q1 Loss Per Share $0.11

* Q1 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S

BRIEF-Cerus Announces Health Canada Approval Of The Intercept Blood System For Platelets

* CERUS ANNOUNCES HEALTH CANADA APPROVAL OF THE INTERCEPT BLOOD SYSTEM FOR PLATELETS Source text for Eikon: Further company coverage:

BRIEF-Cerus’ Redes Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

* ’ REDES PHASE 3 RED BLOOD CELL STUDY EXPANDS INTO THE CONTINENTAL U.S.

BRIEF-Cerus Announces The Fourth Biologics License Application Approval For A U.S. Blood Center Customer

* CERUS ANNOUNCES THE FOURTH BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR A U.S. BLOOD CENTER CUSTOMER

BRIEF-Cerus Corp Reports Q4 Loss Per Share $0.10

* ORATION REPORTS RECORD FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-Cerus Announces Pricing Of Public Offering Of Common Stock

* CERUS CORP - ‍PRICING OF PUBLIC OFFERING OF ITS COMMON STOCK FOR PROCEEDS OF $50.0 MILLION, BEFORE DEDUCTING ESTIMATED OFFERING EXPENSES PAYABLE BY CERUS​ Source text for Eikon: Further company coverage:

BRIEF-Cerus Announces Public Offering Of Common Stock

* CERUS CORP - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints

* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS

Select another date: